Compugen To Present Immune Checkpoint Findings At 3 US Conferences

October 7, 2014 | The Israeli drug discovery company Compugen announced that certain aspects of its predictive approach to therapeutics discovery in novel immune checkpoints will be presented at upcoming scientific conferences. The presentations that will be given at up to three such events will also include the experimental results from some of the immune checkpoint trials in cancer immunotherapy and autoimmune diseases. The three events that the company will present at are the 22nd Annual International Cancer Immunotherapy Symposium in New York City, The Society for Immunotherapy of Cancer Annual Meeting in Baltimore, Maryland and the American College of Rheumatology Annual Meeting held in Boston. Compugen is a publicly traded company that was founded in 1993 by Eli Mintz, Simchon Faigler and Amir Natan.